secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2022-06-08T23:59:59+00:00
Accession:  0001104659-22-069317
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel FORWARD Phase 3 trial of fostamatinib in wAIHA misses primary endpoint overall; positive regional signals seen
--------------------------------------------------------------------------------

- Primary endpoint of durable hemoglobin response not met: fostamatinib 35.6% vs placebo 26.7% (p=0.398).
- Post-hoc analysis: U.S./Canada/Australia/Western Europe showed significant benefit (36.0% vs 10.7%, p=0.03); Eastern Europe did not (35% vs 52.9%, p=0.304).
- Safety profile consistent with prior data; most common AEs: diarrhea (26.7%), hypertension (24.4%), fatigue (15.6%).
- Rigel plans further data analysis and discussion with FDA regarding regional differences.
- 71 of 90 patients (79%) enrolled in open-label extension study; data to be reported later.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922069317/0001104659-22-069317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922069317/tm2217976d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-069317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer